Healthcare provider profile · identity verified

Olivia J Carter, MD

Family Practice · CAMDEN, ME · NPI 1992200356

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	240	75
Levothyroxine Sodium	Levothyroxine Sodium	184	54
Amlodipine Besylate	Amlodipine Besylate	133	38
Lisinopril	Lisinopril	123	35
Rosuvastatin Calcium	Rosuvastatin Calcium	111	37
Gabapentin	Gabapentin	110	38
Omeprazole	Omeprazole	105	36
Fluoxetine Hcl	Fluoxetine Hcl	97	19
Sertraline Hcl	Sertraline Hcl	97	27
Losartan Potassium	Losartan Potassium	83	26
Bupropion Xl	Bupropion Hcl	77	27
Metoprolol Succinate	Metoprolol Succinate	70	20
Simvastatin	Simvastatin	70	18
Eliquis	Apixaban	67	12
Albuterol Sulfate Hfa	Albuterol Sulfate	59	31
Mounjaro	Tirzepatide	58	11
Hydrochlorothiazide	Hydrochlorothiazide	57	15
Trazodone Hcl	Trazodone Hcl	57	19
Escitalopram Oxalate	Escitalopram Oxalate	55	15
Metformin Hcl	Metformin Hcl	51	17
Alendronate Sodium	Alendronate Sodium	48	14
Mirtazapine	Mirtazapine	39	12
Fluticasone Propionate	Fluticasone Propionate	37	18
Triamcinolone Acetonide	Triamcinolone Acetonide	37	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	15
Jardiance	Empagliflozin	35	suppressed
Metformin Hcl Er	Metformin Hcl	34	11
Ozempic	Semaglutide	34	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	32	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	31	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Tramadol Hcl	Tramadol Hcl	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	28	suppressed
Atenolol	Atenolol	27	suppressed
Famotidine	Famotidine	26	suppressed
Glipizide Er	Glipizide	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Celecoxib	Celecoxib	21	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	21	19
Naltrexone Hcl	Naltrexone Hcl	21	11
Allopurinol	Allopurinol	20	suppressed
Furosemide	Furosemide	20	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Loperamide	Loperamide Hcl	20	suppressed
Lorazepam	Lorazepam	20	suppressed
Lovastatin	Lovastatin	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Prednisone	Prednisone	19	16
Propranolol Hcl	Propranolol Hcl	19	suppressed
Repatha Sureclick	Evolocumab	18	suppressed
Solifenacin Succinate	Solifenacin Succinate	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Arexvy	Rsvpref3 Antigen/As01e/Pf	16	16
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	16	suppressed
Estradiol	Estradiol	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Finasteride	Finasteride	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Sulindac	Sulindac	13	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Nystatin	Nystatin	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	11	11
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Rybelsus	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error